{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:43Z","timestamp":1792088203344,"version":"4.4.0"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"DOI":"10.13039\/100012021","name":"Iran University\n                   of Medical Sciences","doi-asserted-by":"crossref","award":["960220631570"],"award-info":[{"award-number":["960220631570"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>\n            Background Glucagon-like petide-1 (GLP-1) agonists such as liraglutide\n                        are widely employed in type 2 diabetes due to their glucose reducing\n                        properties and small risk of hypoglycemia. Recently, it has been shown that\n                        GLP-1agonists can inhibit breast cancer cells growth. Nonetheless, concerns\n                        are remained about liraglutide tumor promoting effects as stated by\n                        population studies.<\/jats:p><jats:p>\n            Material and Methods We evaluated the effects liraglutide on\n                        proliferation of MDA-MB-231 cells by MTT assay and then ATP-binding cassette\n                        (ABC) transporters expressions assessed by Real time PCR. Statistical\n                        comparisons were made using one-way analysis of variance followed by a post\n                        hoc Dunnett test.<\/jats:p><jats:p>\n            Results Here, we report that liraglutide can stimulate the growth of\n                        highly invasive triple negative cell line MDA-MB-231; which can be\n                        attributed to AMPK-dependent epithelial-mesenchymal transition (EMT)\n                        happening in MDA-MB-231 context. Toxicity effects were only observed with\n                        concentrations far above the serum liraglutide concentration. ATP-binding\n                        cassette (ABC) transporters expressions were upregulated, indicating the\n                        possible drug resistance and increased EMT.<\/jats:p><jats:p>\n            Conclusion In conclusion, these results suggest that liraglutide\n                        should be used with caution in patients who are suffering or have the\n                        personal history of triple negative breast cancer. However, more detailed\n                        studies are required to deepen understanding of liraglutide consequences in\n                        triple negative breast cancer. \u25b6Graphical Abstract.\n                    <\/jats:p>","DOI":"10.1055\/a-1345-7890","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:02:38Z","timestamp":1611273758000},"page":"307-311","source":"Crossref","is-referenced-by-count":15,"title":["Growth Promotion and Increased ATP-Binding Cassette Transporters\n                    Expression by Liraglutide in Triple Negative Breast Cancer Cell Line\n                    MDA-MB-231"],"prefix":"10.1055","volume":"71","author":[{"given":"Amir","family":"Shadboorestan","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares\n                    University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Tarighi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, Faculty of Allied Medicine, Iran\n                    University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Koosha","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy and Pharmaceutical Biotechnology, School of\n                    Pharmacy, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homa","family":"Faghihi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Iran University of\n                    Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Ghahremani","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran\n                    University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Montazeri","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy and Pharmaceutical Biotechnology, School of\n                    Pharmacy, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4158\/EP10357.RA","article-title":"Significantly increased risk of cancer in patients with diabetes mellitus: A\n                    systematic review and meta-analysis","volume":"17","author":"H Noto","year":"2011","journal-title":"Endocr Pract"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: Umbrella review of meta-analyses of observational\n                    studies","volume":"350","author":"K K Tsilidis","year":"2015","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-015-3323-5","article-title":"The association between diabetes and breast cancer stage at diagnosis: A\n                    population-based study","volume":"150","author":"L L Lipscombe","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort\n                    of U.S. adults","volume":"348","author":"E E Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"ref5","first-page":"809291","article-title":"Metabolic syndrome and triple-negative breast cancer: A new paradigm","author":"A A Davis","year":"2012","journal-title":"Int J Breast Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.ejim.2009.05.012","article-title":"Unraveling the science of incretin biology","volume":"20","author":"M A Nauck","year":"2009","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"L L Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its\n                    ligands","volume":"166","author":"D Donnelly","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are\n                    rapidly degraded from the NH2-terminus in type II diabetic patients and in\n                    healthy subjects","volume":"44","author":"C F Deacon","year":"1995","journal-title":"Diabetes"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1345\/aph.1M134","article-title":"Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes\n                    mellitus","volume":"43","author":"J J Neumiller","year":"2009","journal-title":"Ann Pharmacother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/en.2004-0015","article-title":"Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in\n                    the pancreas, gut, and central nervous system","volume":"145","author":"P L Brubaker","year":"2004","journal-title":"Endocrinology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","article-title":"The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth\n                    of breast cancer cells","volume":"132","author":"H Ligumsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s13277-015-4104-9","article-title":"Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast\n                    cancer cells","volume":"37","author":"G Fidan-Yaylali","year":"2016","journal-title":"Tumour Biol"},{"key":"ref14","first-page":"i5340","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2\n                    diabetes: population based cohort study using the UK Clinical Practice Research\n                    Datalink","volume":"355","author":"B M Hicks","year":"2016","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"i5519","DOI":"10.1136\/bmj.i5519","article-title":"Glucagon-like peptide-1 receptor agonists and risk of breast cancer","volume":"355","author":"S D Bolen","year":"2016","journal-title":"BMJ"},{"key":"ref16","first-page":"5202","article-title":"Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human\n                    breast cancer cells through downregulation of microRNA-27a expression","volume":"17","author":"W Zhao","year":"2018","journal-title":"Mol Med Rep"},{"key":"ref17","first-page":"3147","article-title":"The story of MCF-7 breast cancer cell line: 40 years of experience in\n                    research","volume":"35","author":"S Comsa","year":"2015","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential\n                    for in vivo targeting","volume":"48","author":"M Korner","year":"2007","journal-title":"J Nucl Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell\n                    inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"N M Krasner","year":"2014","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-016-0985-7","article-title":"The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport\n                    by an AMPK-dependent mechanism","volume":"14","author":"F Andreozzi","year":"2016","journal-title":"J Transl Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2014.01.018","article-title":"The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic\n                    regulator","volume":"356","author":"B Faubert","year":"2015","journal-title":"Cancer Lett"},{"key":"ref22","first-page":"131: jcs208314","article-title":"AMP-activated protein kinase promotes epithelial-mesenchymal transition in\n                    cancer cells through Twist1 upregulation","author":"M Saxena","year":"2018","journal-title":"J Cell Sci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"22850","DOI":"10.1074\/jbc.M114.576371","article-title":"5\u2032-AMP-activated protein kinase (AMPK) supports the growth of aggressive\n                    experimental human breast cancer tumors","volume":"289","author":"K R Laderoute","year":"2014","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: Clinical pharmacokinetics and\n                    pharmacodynamics","volume":"55","author":"L V Jacobsen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/cddis.2011.61","article-title":"Transcription factors that mediate epithelial-mesenchymal transition lead to\n                    multidrug resistance by upregulating ABC transporters","volume":"2","author":"M Saxena","year":"2011","journal-title":"Cell Death Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","article-title":"ABCG2: A potential marker of stem cells and novel target in stem cell and cancer\n                    therapy","volume":"86","author":"X W Ding","year":"2010","journal-title":"Life Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/JME-14-0051","article-title":"ABCG2\/BCRP gene expression is related to epithelial-mesenchymal\n                    transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)","volume":"52","author":"E Mato","year":"2014","journal-title":"J Mol Endocrinol"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1345-7890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T23:00:02Z","timestamp":1625094002000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1345-7890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":27,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,6,30]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1345-7890","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]}}}